sepantronium

a survivin suppressant with antineoplastic activity

Also Known As:

1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho(2,3-d)imidazolium; 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho(2,3-d)imidazolium bromide; YM 155; YM-155; YM155; sepantronium bromide; sepantronium cation; sepantronium ion

Networked: 211 relevant articles (18 outcomes, 60 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kita, Aya: 19 articles (09/2018 - 09/2007)
2.	Yamanaka, Kentaro: 18 articles (09/2018 - 09/2007)
3.	Nakahara, Takahito: 14 articles (02/2013 - 09/2007)
4.	Kaneko, Naoki: 10 articles (09/2018 - 06/2011)
5.	Sasamata, Masao: 10 articles (10/2012 - 09/2007)
6.	Takeuchi, Masahiro: 8 articles (09/2012 - 09/2007)
7.	Mori, Masamichi: 7 articles (04/2014 - 09/2007)
8.	Kinoyama, Isao: 6 articles (09/2012 - 09/2007)
9.	Koutoku, Hiroshi: 6 articles (09/2012 - 06/2011)
10.	Minematsu, Tsuyoshi: 6 articles (12/2011 - 07/2008)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2022 - "Ym155 potently induces cell death of many types of cancer cells in preclinical studies. " 01/01/2021 - "YM155 is originally developed as an expression suppressant of BIRC5 (an anti-apoptotic molecule) and it has reached Phase I/II clinical trials for the treatment of variety types of cancer. " 09/01/2018 - "Similarly, in vivo studies using tumor xenografted mice showed that tumors sensitive to YM155 demonstrated robust uptake of [11C]YM155, whereas insensitive tumors demonstrated low uptake. " 09/01/2018 - "Although YM155 induces tumor regression in various tumor types in vivo, phase I and II studies demonstrated responding and non-responding patient populations. " 04/24/2017 - "In this study, we investigated the anti-tumor effects of YM155 on OSCC cells and then examined its molecular mechanisms. "
2.	Osteosarcoma (Osteogenic Sarcoma) 05/01/2022 - "In osteosarcoma, miR‑218 showed a wider range of therapeutic efficacy compared with YM155, suggesting that miR‑218 should be evaluated as a treatment target." 09/13/2016 - "Collectively, our study suggests that YM155 holds promise for patients with osteosarcoma. " 05/01/2022 - "Osteosarcoma cell lines were subcutaneously injected into immunodeficient mice; the mice were then treated with miR‑218 or YM155 to assess the anti‑tumor effects of these agents. " 08/01/2015 - "YM155 exerts a growth inhibitory effect on human osteosarcoma in vitro and in vivo." 01/01/2015 - "Taken together, the evidence presented here supports the favorable preclinical evaluation that YM155 could overcome DOX the resistance in tumor cells thereby enhancing the effectiveness of DOX in OS, suggesting that YM155 in combination with DOX has potential in the treatment of osteosarcoma. "
3.	Pancreatic Neoplasms (Pancreatic Cancer) 01/01/2015 - "Together, these findings suggest that YM155 could be a novel therapeutic agent for pancreatic cancer." 01/01/2015 - "The aim of our study is to understand the mechanisms by which YM155 functions in pancreatic cancer cells. " 01/01/2012 - "We suggest that YM155 has potential as a therapeutic agent in the treatment of pancreatic cancer." 01/01/2012 - "YM155 induces EGFR suppression in pancreatic cancer cells." 01/01/2012 - "YM155 also inhibited tumor growth in vivo, reducing the size of pancreatic cancer cell line MIAPaCa-2 xenografts by 77.1% on day 31. "
4.	Breast Neoplasms (Breast Cancer) 05/30/2015 - "In vitro assays indicate that YM155 more efficiently triggers cell death in breast cancer cells (including these with stem-cell like properties) than in non tumorigenic mammary cells. " 05/30/2015 - "We herein show that YM155 exerts single agent toxicity on primary breast cancer cells grown in an ex vivo assay preserving tumor microenvironment. " 01/01/2015 - "Interestingly, YM155 also induced XIAP degradation and the degradation of XIAP might play an important role in YM155-induced autophagy in breast cancer cells. " 01/01/2015 - "Western blot analysis, flow cytometric analysis, reverse transcription-PCR, fluorescent microscopy and comet assay were used to determine the molecular mechanism of action of YM155 in different breast cancer cell lines. " 01/01/2015 - "Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer."
5.	Neuroblastoma 10/13/2016 - "The efficacy of YM155 was determined in neuroblastoma cell lines and their sublines with acquired resistance to clinically relevant drugs. " 02/01/2023 - "YM155 inhibits neuroblastoma growth through degradation of MYCN: A new role as a USP7 inhibitor." 03/02/2020 - "In conclusion, the large cell line panel was necessary to reveal an unanticipated complexity of the YM155 response in neuroblastoma cell lines with acquired drug resistance. " 03/02/2020 - "Here, we tested YM155 in 101 neuroblastoma cell lines (19 parental cell lines, 82 drug-adapted sublines). " 10/13/2016 - "Here we investigated the efficacy and mechanism of action of YM155 in neuroblastoma cells with acquired drug resistance. "

Related Drugs and Biologics

1.	Survivin
2.	sepantronium
3.	Docetaxel (Taxotere)
4.	Cisplatin (Platino)
5.	Gemcitabine
6.	Platinum Compounds (Compounds, Platinum)
7.	Alemtuzumab (Campath)
8.	1-phenyl-3,3-dimethyltriazene (PDT)
9.	Small Interfering RNA (siRNA)
10.	Death Domain Receptors

Related Therapies and Procedures

1.	Therapeutics
2.	Transplantation
3.	Castration
4.	Drug Therapy (Chemotherapy)
5.	Cell- and Tissue-Based Therapy (Cell Therapy)